McFarlane Neil F. 4
4 · ZEVRA THERAPEUTICS, INC. · Filed Oct 11, 2023
Insider Transaction Report
Form 4
McFarlane Neil F.
DirectorPresident and CEO
Transactions
- Award
Restricted Stock Unit
2023-10-10+200,000→ 200,000 totalExercise: $0.00→ Common Stock (200,000 underlying) - Award
Stock Option (right to buy)
2023-10-10+600,000→ 600,000 totalExercise: $4.75Exp: 2033-10-09→ Common Stock (600,000 underlying)
Footnotes (3)
- [F1]The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, October 10, 2023.
- [F2]Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares underlying the option will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
- [F3]Grant to the Reporting Person of restricted stock units ("RSU") under the Issuer's 2023 Employment Inducement Award Plan (the "Plan"). 25% of the shares will vest on October 10, 2024 and the remaining 75% of the shares will vest in equal annual installments thereafter, provided that at the relevant vesting dates such optionee's employment relationship has not been terminated as defined in the Plan. All shares will vest in full and become immediately exercisable upon a change of control of the Issuer or if the Reporting Person is terminated without cause or resigns for good reason.